vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $105.1M, roughly 1.3× OLAPLEX HOLDINGS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -12.5%, a 47.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 4.3%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $32.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 3.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
ADMA vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $105.1M |
| Net Profit | $49.4M | $-13.1M |
| Gross Margin | 63.8% | 68.0% |
| Operating Margin | 45.1% | -4.3% |
| Net Margin | 35.5% | -12.5% |
| Revenue YoY | 18.4% | 4.3% |
| Net Profit YoY | -55.9% | -48.9% |
| EPS (diluted) | $0.20 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $105.1M | ||
| Q3 25 | $134.2M | $114.6M | ||
| Q2 25 | $122.0M | $106.3M | ||
| Q1 25 | $114.8M | $97.0M | ||
| Q4 24 | $117.5M | $100.7M | ||
| Q3 24 | $119.8M | $119.1M | ||
| Q2 24 | $107.2M | $103.9M | ||
| Q1 24 | $81.9M | $98.9M |
| Q4 25 | $49.4M | $-13.1M | ||
| Q3 25 | $36.4M | $11.1M | ||
| Q2 25 | $34.2M | $-7.7M | ||
| Q1 25 | $26.9M | $465.0K | ||
| Q4 24 | $111.9M | $-8.8M | ||
| Q3 24 | $35.9M | $14.8M | ||
| Q2 24 | $32.1M | $5.8M | ||
| Q1 24 | $17.8M | $7.7M |
| Q4 25 | 63.8% | 68.0% | ||
| Q3 25 | 56.3% | 69.1% | ||
| Q2 25 | 55.1% | 71.2% | ||
| Q1 25 | 53.2% | 69.5% | ||
| Q4 24 | 53.9% | 66.3% | ||
| Q3 24 | 49.8% | 68.6% | ||
| Q2 24 | 53.6% | 69.7% | ||
| Q1 24 | 47.8% | 72.1% |
| Q4 25 | 45.1% | -4.3% | ||
| Q3 25 | 38.0% | 3.7% | ||
| Q2 25 | 35.1% | -1.1% | ||
| Q1 25 | 30.4% | 8.7% | ||
| Q4 24 | 32.6% | 3.0% | ||
| Q3 24 | 33.1% | 23.5% | ||
| Q2 24 | 36.6% | 15.7% | ||
| Q1 24 | 26.7% | 19.8% |
| Q4 25 | 35.5% | -12.5% | ||
| Q3 25 | 27.1% | 9.7% | ||
| Q2 25 | 28.1% | -7.3% | ||
| Q1 25 | 23.4% | 0.5% | ||
| Q4 24 | 95.2% | -8.7% | ||
| Q3 24 | 30.0% | 12.4% | ||
| Q2 24 | 29.9% | 5.6% | ||
| Q1 24 | 21.7% | 7.8% |
| Q4 25 | $0.20 | $-0.02 | ||
| Q3 25 | $0.15 | $0.02 | ||
| Q2 25 | $0.14 | $-0.01 | ||
| Q1 25 | $0.11 | $0.00 | ||
| Q4 24 | $0.45 | $-0.01 | ||
| Q3 24 | $0.15 | $0.02 | ||
| Q2 24 | $0.13 | $0.01 | ||
| Q1 24 | $0.08 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $318.7M |
| Total DebtLower is stronger | $72.1M | $352.3M |
| Stockholders' EquityBook value | $477.3M | $879.4M |
| Total Assets | $624.2M | $1.5B |
| Debt / EquityLower = less leverage | 0.15× | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $318.7M | ||
| Q3 25 | $61.4M | $286.4M | ||
| Q2 25 | $90.3M | $289.3M | ||
| Q1 25 | $71.6M | $580.9M | ||
| Q4 24 | $103.1M | $586.0M | ||
| Q3 24 | $86.7M | $538.8M | ||
| Q2 24 | $88.2M | $507.9M | ||
| Q1 24 | $45.3M | $507.5M |
| Q4 25 | $72.1M | $352.3M | ||
| Q3 25 | $72.4M | $352.1M | ||
| Q2 25 | — | $351.9M | ||
| Q1 25 | — | $649.1M | ||
| Q4 24 | $72.3M | $650.5M | ||
| Q3 24 | — | $651.8M | ||
| Q2 24 | — | $653.1M | ||
| Q1 24 | — | $654.4M |
| Q4 25 | $477.3M | $879.4M | ||
| Q3 25 | $431.2M | $888.7M | ||
| Q2 25 | $398.3M | $874.2M | ||
| Q1 25 | $373.4M | $878.3M | ||
| Q4 24 | $349.0M | $874.4M | ||
| Q3 24 | $231.9M | $879.7M | ||
| Q2 24 | $188.3M | $863.3M | ||
| Q1 24 | $153.7M | $855.7M |
| Q4 25 | $624.2M | $1.5B | ||
| Q3 25 | $568.7M | $1.5B | ||
| Q2 25 | $558.4M | $1.5B | ||
| Q1 25 | $510.6M | $1.8B | ||
| Q4 24 | $488.7M | $1.8B | ||
| Q3 24 | $390.6M | $1.8B | ||
| Q2 24 | $376.4M | $1.8B | ||
| Q1 24 | $350.9M | $1.8B |
| Q4 25 | 0.15× | 0.40× | ||
| Q3 25 | 0.17× | 0.40× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | 0.21× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $32.7M |
| Free Cash FlowOCF − Capex | $34.6M | $32.6M |
| FCF MarginFCF / Revenue | 24.8% | 31.0% |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $32.7M | ||
| Q3 25 | $13.3M | $8.0M | ||
| Q2 25 | $21.1M | $20.9M | ||
| Q1 25 | $-19.7M | $-2.9M | ||
| Q4 24 | $50.2M | $49.7M | ||
| Q3 24 | $25.0M | $33.5M | ||
| Q2 24 | $45.6M | $16.2M | ||
| Q1 24 | $-2.2M | $43.7M |
| Q4 25 | $34.6M | $32.6M | ||
| Q3 25 | $-1.1M | $7.9M | ||
| Q2 25 | $18.7M | $20.8M | ||
| Q1 25 | $-24.4M | $-3.0M | ||
| Q4 24 | $47.5M | $49.2M | ||
| Q3 24 | $24.0M | $33.3M | ||
| Q2 24 | $43.6M | $16.1M | ||
| Q1 24 | $-4.6M | $43.3M |
| Q4 25 | 24.8% | 31.0% | ||
| Q3 25 | -0.8% | 6.9% | ||
| Q2 25 | 15.3% | 19.6% | ||
| Q1 25 | -21.2% | -3.1% | ||
| Q4 24 | 40.4% | 48.9% | ||
| Q3 24 | 20.0% | 28.0% | ||
| Q2 24 | 40.7% | 15.5% | ||
| Q1 24 | -5.6% | 43.7% |
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.3% | 0.4% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 0.5% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 0.72× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -6.27× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 2.26× | ||
| Q2 24 | 1.42× | 2.81× | ||
| Q1 24 | -0.12× | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
